Podcasts about tumors

In dieser Folge spreche ich mit Prof. Dr. med. Olivio Donati, Facharzt für Radiologie, Pionier der Prostatadiagnostik und Professor am Unispital Zürich, sowie Prof. Dr. Thomas Hermanns, einem der führenden Urologen der Schweiz, spezialisiert auf modernste Therapieverfahren am Zentrum für Urologie in Zürich, Klinikum Hirslanden. Prostatakrebs ist die häufigste Tumorerkrankung beim Mann und nach Herz-Kreislauf-Erkrankungen die zweithäufigste Todesursache. Doch nicht jeder Tumor ist gleich gefährlich: Manche bleiben ein Leben lang harmlos, andere explodieren und streuen. Die entscheidende Frage ist daher, wie man die gefährlichen Tumoren frühzeitig erkennt, ohne Männer mit unnötigen Biopsien zu belasten. Wir besprechen, welche Rolle der PSA-Wert, das multiparametrische MRT und genetische Tests in einer individualisierten, mehrstufigen Vorsorgestrategie spielen – und warum gesunder Lebensstil auch bei der Prostata den Unterschied machen kann. In dieser Folge sprechen wir u.a. über folgende Themen: - Warum ist Prostatakrebs bei Männern die zweithäufigste Todesursache nach Herz-Kreislauf-Erkrankungen und wie unterscheiden sich aggressive von harmlosen Tumoren? - Wie beeinflusst die familiäre Vorbelastung – einschließlich Brustkrebs bei der Mutter – das individuelle Risiko für ein Prostatakarzinom? - Weshalb kann ein polygenetischer Test oder die Analyse des BRCA2-Gens entscheidend für eine frühzeitige Vorsorge sein? - Was genau misst der PSA-Wert und warum ist er kein spezifischer Krebsmarker, sondern eher eine Motorenleuchte? - Wie können gutartige Ursachen wie Entzündungen, intensives Radfahren oder Sexualaktivität den PSA-Wert verfälschen? - Was bedeutet multiparametrisch beim MP-MRT und welche drei funktionellen Parameter werden dabei erhoben? - Warum empfehlen erfahrene Radiologen trotz neuer Studienlage weiterhin die Kontrastmittelgabe als Tiebreaker? - Weshalb hat sich die perineale MRT-Fusionsbiopsie gegenüber der klassischen transrektalen Stanzbiopsie durchgesetzt? - Was ist Active Surveillance und für welche Patienten mit Gleason-6-Tumoren ist diese Strategie geeignet? - Wie funktioniert die Da-Vinci-Roboter-Operation und welche Rolle spielt die fokale Therapie als Alternative? - Weshalb ist das Dogma, Männer über 70 nicht mehr zu screenen, im Zeitalter der Longevity überholt? - Was sagt der Stockholm-3-Test aus und warum sehen Experten dessen routinemäßigen Einsatz derzeit noch kritisch? Weitere Informationen zu Prof. Dr. med. Olivio Donati findest du hier: https://www.hirslanden.ch/de/corporate/aerzte/4/prof-dr-med-olivio-donati.htmlhttps://www.linkedin.com/in/olivio-donati-48448/ Weitere Informationen zu Prof. Dr. Thomas Hermanns findest du hier: https://www.hirslanden.ch/de/corporate/aerzte/4/pd-dr-med-thomas-hermanns.html Du interessierst dich für Gesunde Langlebigkeit (Longevity) und möchtest ein Leben lang gesund und fit bleiben, dann folge mir auch auf den sozialen Kanälen bei Instagram, TikTok, Facebook oder YouTube. https://www.instagram.com/nina.ruge.official https://www.tiktok.com/@nina.ruge.official https://www.facebook.com/NinaRugeOffiziell https://www.youtube.com/channel/UCOe2d1hLARB60z2hg039l9g Disclaimer: Ich bin keine Ärztin und meine Inhalte ersetzen keine medizinische Beratung. Bei gesundheitlichen Fragen wende dich bitte an deinen Arzt/deine Ärztin. STY-257

In dieser Folge meines Podcasts „Krebs als zweite Chance – Der Mutmacher Podcast“ spreche ich mit Anja, die seit vielen Jahren mit einer seltenen genetischen Erkrankung lebt. Mit 25 Jahren erhielt sie die Diagnose FAP – Familiäre Adenomatöse Polyposis, eine vererbbare Erkrankung mit stark erhöhtem Krebsrisiko. Aufgrund der Erkrankung wurde ihr bereits früh der Dickdarm entfernt und bis heute gehören regelmäßige Kontrolluntersuchungen zu ihrem Leben. Im Oktober 2023 kam eine weitere schwere Diagnose hinzu: Ein bösartiger Tumor in der Gebärmutter. Es folgten Operation und Chemotherapie – gleichzeitig musste sie weiterhin regelmäßig wegen ihrer FAP zu Magenspiegelungen ins Krankenhaus. Doch Anja hat sich entschieden, das Leben bewusst weiterzugehen. 2024 stand für sie unter dem Motto: „Raus ins Leben.“ Sie war viel unterwegs und hat nach 19 Jahren in wilder Ehe ihren Partner geheiratet. Gleichzeitig trägt sie eine große persönliche Geschichte in sich: Vor genau einem Jahr ist ihre Mutter gestorben – von ihr hat sie auch die genetische Erkrankung FAP geerbt. Im Gespräch erzählt Anja offen über: ✨ das Leben mit einer genetischen Krebsprädisposition ✨ die Diagnose eines bösartigen Tumors in der Gebärmutter ✨ medizinische Herausforderungen und regelmäßige Kontrollen ✨ Trauer, Familie und Neubeginn ✨ warum sie sich entschieden hat, bewusst zu leben Ihre Geschichte zeigt, dass das Leben trotz Krankheit weitergeht – manchmal sogar intensiver als zuvor. ⸻ ✍️ Mehr über Anja Über ihre Erfahrungen schreibt sie auch in ihrem Blog:

Folge 298 | Interview mit Marcel und Michelle Neufeld: Unser größter Albtraum - Gottes größte Nähe (Teil 2) Marcel und Michelle standen vor einer der größten Herausforderungen ihres Lebens: Bei ihrem dritten Kind wurde im Kleinkindalter ein Tumor entdeckt. In dieser Folge erzählen die beiden, wie sie Schritt für Schritt zur endgültigen Diagnose gelangten und wie schließlich der Therapieplan festgelegt wurde. Offen berichten sie darüber, wie die Situation ihre Ehe beeinflusst hat und wie sie die anderen Kinder mit in den Prozess genommen haben. Verpasse diese Folge nicht.Dieses Video wurde durch Spenden ermöglicht. Wir danken für Deine Unterstützung: https://www.sw-radio.com/spenden.htmlHinterlasse uns gerne deine Kommentare und teile diesen Beitrag mit deinen Freunden. Außerdem findest du viele weitere spannende Interviews, Predigten und ähnliches in dem Podcast deep talk. Im Linktree kannst du auswählen, auf welchem Wege du deep talk hören möchtest (Spotify, Telegram, Segenswelle-App...): https://linktr.ee/segenswelle_deeptalk Wenn du uns ein Feedback geben möchtest oder Anregungen hast, dann kontaktiere uns gerne: WhatsApp +49 5231 500 59 88 Telegram https://t.me/SegenswelleInstagram https://www.instagram.com/segenswelle... E-Mail: deeptalk@segenswelle.de Für mehr Informationen zu Radio Segenswelle besuche gerne unsere Website https://www.segenswelle.de  

Today we're joined by Sean MacDonald, CEO of Kainova Therapeutics. With more than twenty years of biotech leadership and deep expertise in strategy and development, Sean is guiding the company through an exciting new chapter.We'll dive into Kainova's innovative GPCR-modulating platform, its promising pipeline, the science behind reversing tumor immunosuppression and targeting inflammation, and the reasons behind the recent rebrand from Domain Therapeutics to Kainova Therapeutics.We'll also be taking a look at the broader oncology landscape—what's hot, who's investing big, and where the biggest opportunities and challenges lie.01:09 – Meet Sean Macdonald05:40 – Kainova's GPCR platform and therapeutic focus08:57 – The story and meaning behind the Kainova rebrand10:25 – Series B funding and pipeline programs16:43 – Exciting trends and innovations in oncology29:17 – Upcoming milestones and future plansInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: GPCR therapies: Eight promising biotechs hacking the cell signaling pathwayEpisode 182: Building a smart oncology pipeline with Cumulus OncologyEpisode 34: eClinical Solutions, GPCR Therapeutics, Orbsen Therapeutics

For patient referrals: call 480-256-6444Can ultrasound liquefy tumors? In this episode of Beyond the Rounds, we explore histotripsy — a novel, non-thermal ultrasound therapy that can destroy tumors without surgery, heat, or radiation. Dr. Nolan Fisher sits down with surgical oncologist Dr. Michael Choti, Chief of Surgery at Banner MD Anderson Cancer Center, to discuss how this emerging technology may change the way liver tumors are treated.Using focused ultrasound energy to create microscopic cavitation bubbles, histotripsy mechanically breaks down tumor tissue while sparing critical structures like blood vessels and bile ducts. The result: precise tumor destruction in locations that may be difficult or impossible to treat with traditional surgery or thermal ablation.This episode explores how histotripsy works, where it fits in today's treatment landscape, and why clinicians should remain both excited and cautious as the technology evolves.This episode is designed for physicians, advanced practice providers, and clinicians who want a practical understanding of emerging technologies in surgical oncology and liver tumor management.What We Cover• What histotripsy is and how cavitation-based ultrasound destroys tumors• Why histotripsy differs from thermal ablation techniques• The “heat sink effect” and why tumors near blood vessels are difficult to treat• How histotripsy may expand treatment options for liver tumors• Using histotripsy as a bridge to liver transplant• The potential immune effects of tumor liquefaction (abscopal effect)• When histotripsy is appropriate — and when it's not• Current FDA approvals and ongoing research• Why careful patient selection and multidisciplinary evaluation matterKey Topics for CliniciansLiver tumorsColorectal liver metastasesHepatocellular carcinoma (HCC)Liver transplant bridging therapyImage-guided tumor ablationHistotripsy technologySurgical oncology innovationMultidisciplinary cancer careAbout Our GuestDr. Michael Choti is Chief of Surgery at Banner MD Anderson Cancer Center and a nationally recognized surgical oncologist specializing in gastrointestinal and hepatobiliary cancers. His career has focused on liver tumors, colorectal cancer metastases, and advancing surgical and minimally invasive treatments for complex cancers. He previously served as Chair of the Department of Surgery at UT Southwestern and trained at Yale, the University of Pennsylvania, and Memorial Sloan Kettering Cancer Center.How to Refer a PatientIf you believe a patient may benefit from evaluation at Banner MD Anderson Cancer Center:Banner Health providers: Use Cerner's Ambulatory Referral Management (ARM) tool.Community providers:Fax referrals to 480-256-4607or call 480-256-6444 to schedule a patient for evaluation.DisclaimerThis podcast is intended for educational purposes only and is designed for a clinical audience. Any patient scenarios discussed are modified and de-identified to protect privacy. No protected health information (PHI) is disclosed. The information presented should not replace independent medical judgment or individualized patient care decisions.Subscribe to Beyond the Rounds for physician-focused conversations on clinical innovation, specialty collaboration, and evolving standards of care.

Tumor-infiltrating lymphocyte (TIL) cell therapy is a promising option for patients with advanced melanoma, but logistical and referral challenges can be a barrier to care. In this episode, CANCER BUZZ speaks with Lilit Karapetyan, MD, MS, FACP, medical oncologist at Moffit Cancer Center and Research Institute, an authorized treatment center (ATC) for TIL cell therapy, and Raju Vaddepally, MD, hematologist-oncologist at Florida Cancer Specialists, a non-ATC, about the referral process. Both guests discuss the relationship between their cancer programs, offering actionable tips on how to streamline the identification and referral of melanoma patients for TIL therapy across institutions. Guests:  Lilit Karapetyan, MD, MS, FACP Medical Oncologist Moffitt Cancer Center and Research Institute Tampa, FL Raju Vaddepally, MD   Hematologist-Oncologist Florida Cancer Specialists Naples, FL  "It is extremely important that providers think about this earlier, because the huge issue that we have with TIL therapy is that we get a lot of patients referred but unfortunately, they are no longer fit to proceed with the therapy." - Lilit Karapetyan, MD, MS, FACP "Cancer care can be so fragmented and always requires multidisciplinary input, whether it be within the town or going to an academic center, so we do have a specialized department in which they handle all these referrals." - Raju Vaddepally, MD Resources ACCC TIL Therapy Resources ACCCBuzz Blog: Streamlining TIL Cell Therapy: ACCC Resources to Improve Referral Pathways and Academic–Community Coordination CANCER BUZZ: Developments in TIL Cell Therapy  

In this episode of Lung Cancer Considered, host Dr. Stephen Liu is joined by Dr. Sara Pilotto and Dr. Jonathan Riess for a virtual tumor board discussion on the management of metastatic EGFR exon 19 NSCLC . Using a complex case featuring discordant biomarker results and brain metastases, the panel explores first-line treatment strategies including osimertinib monotherapy, FLAURA2 (osimertinib plus chemotherapy), and MARIPOSA (amivantamab plus lazertinib), as well as sequencing at progression, re-biopsy, CNS considerations, and the evolving role of local consolidation and clinical trials.

To have Dr. Morse answer a question, visit: https://drmorses.tv/ask/ All of Dr. Morse's and his son's websites under one roof: https://handcrafted.health/ Facebook Page: https://www.facebook.com/handcrafted.health 00:00:00 - Intro 00:01:33 - Paroxysmal Atrial Fibrillation (PAF) 00:23:31- Torn Meniscus - Cartilage Loss 00:38:57 - Endometriosis - Unwanted Hair Growth - Excessive Hair Loss - Acne - Cystic Gut 01:03:41 - Benign Tumor 01:13:50 - Growths 00:01:33 - Paroxysmal Atrial Fibrillation (PAF) AFib has been running my life for the past year with multiple weekly episodes. 00:23:31- Torn Meniscus - Cartilage Loss I am now in constant pain and have great difficulty walking. 00:38:57 - Endometriosis - Unwanted Hair Growth - Excessive Hair Loss - Acne - Cystic Gut My main health issue is, very severe and painful menstrual periods with heavy bleeding. 01:03:41 - Benign Tumor My 5-year-old daughter has a benign tumor, I'm trying to find a solution for her.  01:13:50 - Growths The latest one I have is hard and sometimes pulses a little bit.

Was passiert in unserem Körper in den ersten Minuten eines Infekts?Und: Kann man sein Immunsystem wirklich stärken – oder ist das ein Mythos?In dieser Folge des ERCM Medizin Podcasts spricht Prof. Dr. rer. nat. Christine Falk, eine der führenden Immunologinnen Deutschlands, über die faszinierende Funktionsweise unserer Immunabwehr – und darüber, wie moderne Immuntherapien derzeit die Medizin verändern.Weitere Themen in dieser Episode:Wie angeborenes und erworbenes Immunsystem zusammenarbeiten.Die Rolle der natürlichen Killerzellen – unsere körpereigene „Spezialeinheit“.Wie Schlafmangel, Stress und Bewegung über die Abwehrkräfte entscheiden.Welche Bedeutung die Ernährung und das Darmmikrobiom für die Immunbalance haben.Was Immunkompetenz wirklich heißt – und warum sie weit mehr ist als nur eine hohe Anzahl an Antikörpern.Wir werfen auch einen Blick in die Zukunft der Krebsmedizin – mit Checkpoint-Inhibitoren, CAR-T-Zellen („lebende Medikamente“) und personalisierten Zelltherapien.Besonders spannend: Frau Prof. Falk erklärt, warum Tumor- und Transplantationsimmunologie zwei Seiten derselben Medaille sind – und wie dieses Wissen Therapien revolutioniert."Der ERCM Medizin Podcast" Social & Webseite:Instagram: https://www.instagram.com/ercm.podcast/TikTok: https://www.tiktok.com/@ercm.podcast?lang=de-DEWebseite: http://www.erc-munich.comKontakt: podcast@erc-munich.com Prof. Dr. Christine Falk:Medizinische Hochschule Hannover: https://www.mhh.de/institute-zentren-forschungseinrichtungen/transplantations-immunologieÜber das ERCM:Im Europäischen Radiochirurgie Centrum München (ERCM) setzen wir seit über 20 Jahren auf präzise Tumortherapien: hochmoderne Radiochirurgie und innovative Medizintechnologien zur gezielten und schonenden Behandlung verschiedener Tumoren – gutartige Neubildungen ebenso wie schwere Krebserkrankungen. Jahr für Jahr schenken uns mehr als 1.000 Patientinnen und Patienten ihr Vertrauen auf dem Weg zu einer individuell abgestimmten Therapie. Unser Ziel: Personalisierte, präzise und vor allem patientenzentrierte Behandlungen, die auf eine effektive und nebenwirkungsarme Therapie bei guter Lebensqualität fokussieren.(00:00:00) Intro (00:05:14) Was passiert bei einem viralen Infekt? Die ersten Stunden der Immunantwort (00:10:07) Angeborenes vs. erworbenes Immunsystem: Die zwei Säulen unserer Abwehr (00:13:03) Die Thymusdrüse und Immunalterung: Warum das Immunsystem im Alter schwächer wird (00:15:38) Tumor- und Transplantationsimmunologie: Zwei Seiten derselben Medaille (00:20:10) Immunsurveillance: Bekämpft unser Körper ständig Krebszellen? (00:30:22) Natürliche Killerzellen: Die Kampftruppe des Immunsystems (00:33:01) Schlaf und Immunsystem: Wie viel Einfluss hat Schlafmangel wirklich? (00:36:13) Immunsystem stärken: Was funktioniert wirklich? (00:41:01) Das Darm-Mikrobiom und seine Rolle für die Immunität (00:42:40) Supplements und Vitamine: Sinnvoll oder Placebo? (00:44:38) Checkpoint-Inhibitoren: Der Nobelpreis und die Revolution der Krebstherapie (00:51:36) CAR-T-Zelltherapie: Künstliche Killerzellen gegen Krebs und Autoimmunerkrankungen (00:57:05) CAR-T-Zellen bei Alzheimer: Neue Hoffnung gegen Amyloid-Plaques? (01:04:05) Statine und Immuntherapie: Überraschende Synergien (01:07:46) Die Zukunft der Immunologie: Personalisierte Medizin und Gentherapie (01:10:43) Drei Tipps für ein gesundes Immunsystem#Immunsystem #Killerzellen #Immunologie #Krebstherapie #CheckpointInhibitoren #CARTZellen #Autoimmunerkrankungen #Transplantation #Prävention #ERCMPodcast #ChristineFalk #Immuntherapie #Gesundheit #Tumorimmunologie

Guest: Shiraz Baboo – Reality Addiction Expert, Author of How to Rewrite Reality, and Founder of Energetic MagicEpisode Focus: How unconscious stories shape our physical reality, from chronic illness to financial blocks, and the radical process of rewriting them for lasting transformation.All Episodes can be found at ⁠⁠⁠https://www.podpage.com/speaking-podcast/⁠⁠ All about Roy / Brain Gym & Virtual Assistants at ⁠⁠⁠https://roycoughlan.com/⁠⁠⁠ #shiraz #ShirazBaboo #bodybuilder  Bio of Shiraz BabooMulti-award-winning author. Reality Interventionist. Creator of the Million Dollar Impact Makers Program.  I have helped thousands of coaches, healers, and high-achieving entrepreneurs break their subconscious addiction to struggle and rewrite the stories keeping them stuck—so they can finally grow their businesses in alignment with who they truly are. At Business Magic Live, I work with you live to release the unconscious patterns that are sabotaging your success… and replace them with the belief, clarity, and aligned action required to build a business that creates real wealth and lasting legacy.Most of the people who come to me already know the strategies. What's been missing isn't knowledge. It's the internal permission to execute, receive, and lead at the level those strategies require.What we Discussed: 00:00 Introduction 01:00 Shiraz's Origin Story: From Bodybuilder to Bedridden04:40 We are protecting ourselves through Stories05:40 How I healed my Back Pain06:30 Fake knee operations gave the same results07:06 A woman with a Tumor that kept disappearing08:00 Lessons learnt from living in different countries11:50 How he kept getting Stopped at Border Control18:00 How to navigate peoples issues without them knowing what is wrong21:00 How he resolved his own Financial issues23:00 My own Financial Struggles23:20 Reviewing Why I have these Fears25:50 If I had Money would it Corrupt me 29:05 Push & Pull Energy32:00 Are you will to step out of the story33:45 Reflecting on how I got seriouly injured every time I was relaxed35:20 Do I always have to be on guard37:00 You Do not have to worry about something to solve it39:00 Common Patterns with clients40:35 His Event Business Magic Live 42:00 People having a yo-yo with Finances43:00 Where to find Shiraz and the EventHow to Contact Shiraz Baboohttps://energeticmagic.com/ https://www.facebook.com/energeticmagic/https://www.linkedin.com/in/shirazbaboo/https://www.youtube.com/energeticmagichttps://www.instagram.com/energetic.magic/ All about Roy / Brain Gym & Virtual Assistants at ⁠⁠⁠https://roycoughlan.com/⁠⁠⁠ 

In this powerful episode of It Takes Balls, Justin Sandler shares his extraordinary journey with a primary mediastinal germ cell tumor, a rare form of testicular cancer that developed in his chest — not his testicles. After months of unexplained chest spasms and being told it was muscular, a CT scan revealed a rapidly growing 14cm tumor pressing against his heart and lung. Doctors at UCLA delivered a sobering reality: without aggressive treatment, the tumor could crush his heart.Justin underwent four rounds of VIP chemotherapy (cisplatin, etoposide, and ifosfamide), administered inpatient 24 hours a day for a week at a time. He openly discusses the brutal side effects of chemo, including severe pain, tinnitus from cisplatin, dangerously low platelet counts, and the emotional toll of living in the oncology ward. After chemo reduced the tumor to a dead mass, he endured an 8.5-hour open chest surgery, losing two-thirds of his right lung, part of his heart wall, and major veins that had to be reconstructed.But the fight didn't end there. Just months later, Justin experienced a life-threatening cardiac tamponade, requiring emergency heart surgery while awake. Through it all, he leaned on a philosophy he calls “Embrace Love Free” — choosing acceptance, mindset, movement, and service over anger and victimhood. From walking hospital laps with his chemo pole to performing a one-man show about his experience, Justin transformed trauma into purpose.This episode explores rare extragonadal germ cell tumors, aggressive chemotherapy for testicular cancer, major thoracic surgery, survivorship challenges, post-cancer depression, and the mental resilience required to rebuild life after treatment. It's a must-listen for anyone facing testicular cancer, rare cancers, chemotherapy, or long-term cancer recovery.Provide your feedback on the podcast:https://www.testicularcancerawarenessfoundation.org/itbsurveyJoin The Ball Room:https://www.testicularcancerawarenessfoundation.org/theballroomWant to be a guest? Apply here:https://www.testicularcancerawarenessfoundation.org/it-takes-balls-submissionsFollow Testicular Cancer Awareness Foundation:⁠https://www.testescancer.orghttps://www.x.com/testescancer⁠⁠https://www.instagram.com/testescancerhttps://www.facebook.com/tca.orgFollow Steven Crocker:https://www.instagram.com/stevencrockerhttps://www.facebook.com/steven.crocker2Connect with Justin:justinsandler.comhttps://www.facebook.com/justinsandlerhttps://www.instagram.com/justinsandlerhttps://www.youtube.com/justinjsandlerhttps://www.tiktok.com/@justinjsandlerhttps://www.linkedin.com/in/justinsandler/Theme song: No Time Like Now - Tom Willner www.tomwillner.com

This interview is disseminated on behalf of GT Biopharma. GT Biopharma (NASDAQ: GTBP) recently received approval from the U.S. Food and Drug Administration (FDA) for a new investigational drug trial for the solid tumor cancer treatment GTB-3650, as the race to develop a cure for cancer intensifies and the solid tumor market grows to $362 billion.Executive Chairman and Chief Executive Officer Michael Breen shares more details about the company's expectations and success indicators for the basket trial of the new medication, as well as upcoming milestones for 2026.Explore GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://youtu.be/VtISaFICJ5gAnd follow us to stay updated: https://www.youtube.com/GlobalOneMedia

Welcome to OncLive On Air®! I'm your host today, Courtney Flaherty.OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.In today's episode, Rashmi Chugh, MD, sat down with OncLive to discuss the ongoing development of the investigational γ-secretase inhibitor varegacestat (formerly AL102) for patients with desmoid tumors.Chugh is a clinical professor and service chief of Internal Medicine at the University of Michigan Medical School, as well as an oncologist at the University of Michigan Rogel Cancer Center in Ann Arbor.In the exclusive interview, Dr Chugh expanded on the current unmet needs and treatment goals in desmoid tumors, the biologic rationale for γ-secretase inhibition and emerging biomarker considerations, and the potential clinical role of varegacestat based on positive topline data from the phase 2/3 RINGSIDE trial (NCT04871282).Of note, submission of a new drug application to the FDA for this agent in progressing desmoid tumors is planned for the second quarter of 2026._____That's all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.If you liked today's episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!Thanks again for listening to OncLive On Air.*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.

Guest: Shiraz Baboo – Reality Addiction Expert, Author of How to Rewrite Reality, and Founder of Energetic Magic Episode Focus: How unconscious stories shape our physical reality, from chronic illness to financial blocks, and the radical process of rewriting them for lasting transformation. All Episodes can be found at ⁠⁠⁠⁠https://www.podpage.com/speaking-podcast/⁠⁠⁠   All about Roy / Brain Gym & Virtual Assistants at ⁠⁠⁠⁠https://roycoughlan.com/⁠⁠⁠⁠   #shiraz #ShirazBaboo #bodybuilder    Bio of Shiraz BabooMulti-award-winning author. Reality Interventionist. Creator of the Million Dollar Impact Makers Program.  I have helped thousands of coaches, healers, and high-achieving entrepreneurs break their subconscious addiction to struggle and rewrite the stories keeping them stuck—so they can finally grow their businesses in alignment with who they truly are. At Business Magic Live, I work with you live to release the unconscious patterns that are sabotaging your success… and replace them with the belief, clarity, and aligned action required to build a business that creates real wealth and lasting legacy.Most of the people who come to me already know the strategies. What's been missing isn't knowledge. It's the internal permission to execute, receive, and lead at the level those strategies require.   What we Discussed:   00:00 Introduction   01:00 Shiraz's Origin Story: From Bodybuilder to Bedridden   04:40 We are protecting ourselves through Stories   05:40 How I healed my Back Pain   06:30 Fake knee operations gave the same results   07:06 A woman with a Tumor that kept disappearing 08:00 Lessons learnt from living in different countries   11:50 How he kept getting Stopped at Border Control   18:00 How to navigate peoples issues without them knowing what is wrong   21:00 How he resolved his own Financial issues   23:00 My own Financial Struggles 23:20 Reviewing Why I have these Fears   25:50 If I had Money would it Corrupt me  29:05 Push & Pull Energy   32:00 Are you will to step out of the story   33:45 Reflecting on how I got seriouly injured every time I was relaxed   35:20 Do I always have to be on guard   37:00 You Do not have to worry about something to solve it   39:00 Common Patterns with clients   40:35 His Event Business Magic Live   42:00 People having a yo-yo with Finances   43:00 Where to find Shiraz and the Event   How to Contact Shiraz Baboo ⁠https://energeticmagic.com/⁠   ⁠https://www.facebook.com/energeticmagic/⁠   ⁠https://www.linkedin.com/in/shirazbaboo/⁠   ⁠https://www.youtube.com/energeticmagic⁠   ⁠https://www.instagram.com/energetic.magic/⁠   All about Roy / Brain Gym & Virtual Assistants at ⁠⁠⁠⁠https://roycoughlan.com/⁠⁠⁠⁠  

Mark Bertagnolli, Chief Operating Officer at ViroMissile, has developed a modified vaccinia virus that can be delivered intravenously to seek out and destroy solid tumors throughout the body and is not dependent on a specific genetic driver of a cancer. The virus has been engineered to be resistant to the body's complement system, allowing it to survive in the bloodstream longer to infect the tumor. This action also turns the tumor microenvironment from cold to hot, signaling the immune system to attack the tumor and potentially working in combination with other treatments like PD-1 inhibitors to make them more effective. Mark explains, "ViroMissile has a modified vaccinia virus, and viruses tend to like to infect tumor cells. So the trick has been how to harness this. And we're on our third generation of virus, and we have a virus that you can inject intravenously that searches for tumors throughout the body, infects them, the body clears the rest of the virus, and the virus embeds itself in the tumors, replicates, spreads, activates the immune system, and destroys the tumors."   "So, the vaccinia virus itself, nobody knows really where it came from, but it ended up being the foundation of the smallpox vaccine, and we get the word vaccine from the vaccinia virus. Our founder was the first to sequence the genome of the vaccinia virus over 30 years ago. For the last 20 years, he's been working on it as an oncolytic agent. And in this particular case, within vaccinia, there are different strains. And he was able to isolate a very specific, never before isolated strain of virus that is resistant to complement attack, and also replicates very quickly in infected cells. So it has two embedded features within it, naturally, that we're able to capitalize on."   #ViroMissile #CancerResearch #Immunotherapy #OncolyticVirus #Biotechnology #MedicalInnovation #CancerTreatment #PrecisionMedicine #HealthcareInnovation #CancerCare #VacciniaVirus viromissile.com Listen to the podcast here  

Mark Bertagnolli, Chief Operating Officer at ViroMissile, has developed a modified vaccinia virus that can be delivered intravenously to seek out and destroy solid tumors throughout the body and is not dependent on a specific genetic driver of a cancer. The virus has been engineered to be resistant to the body's complement system, allowing it to survive in the bloodstream longer to infect the tumor. This action also turns the tumor microenvironment from cold to hot, signaling the immune system to attack the tumor and potentially working in combination with other treatments like PD-1 inhibitors to make them more effective. Mark explains, "ViroMissile has a modified vaccinia virus, and viruses tend to like to infect tumor cells. So the trick has been how to harness this. And we're on our third generation of virus, and we have a virus that you can inject intravenously that searches for tumors throughout the body, infects them, the body clears the rest of the virus, and the virus embeds itself in the tumors, replicates, spreads, activates the immune system, and destroys the tumors."   "So, the vaccinia virus itself, nobody knows really where it came from, but it ended up being the foundation of the smallpox vaccine, and we get the word vaccine from the vaccinia virus. Our founder was the first to sequence the genome of the vaccinia virus over 30 years ago. For the last 20 years, he's been working on it as an oncolytic agent. And in this particular case, within vaccinia, there are different strains. And he was able to isolate a very specific, never before isolated strain of virus that is resistant to complement attack, and also replicates very quickly in infected cells. So it has two embedded features within it, naturally, that we're able to capitalize on."   #ViroMissile #CancerResearch #Immunotherapy #OncolyticVirus #Biotechnology #MedicalInnovation #CancerTreatment #PrecisionMedicine #HealthcareInnovation #CancerCare #VacciniaVirus viromissile.com Download the transcript here

«Die violett eingefärbten Punkte meiner Krebszellen wirkten auf mich fast schön.» Nach ihrer Brustkrebsdiagnose wollte Frau Z. mehr wissen. Sie bat ihre Ärztin, die pathologischen Bilder ihres Tumors sehen zu dürfen und vor allem, sie erklärt zu bekommen. «Den Patientinnen und Patienten damit Sicherheit und Vertrauen zu geben, ist unser Ziel», erklären die Forschenden eines von der Krebsforschung Schweiz unterstützten Projektes. Die Idee dazu stammt vom Pathologen Gieri Cathomas (Institut für Gewebsmedizin und Pathologie, Universität Bern) und wurde gemeinsam mit der Psychoonkologin Marie-Louise Fontana sowie dem Psychoonkologen Alexander Wünsch weiterentwickelt. In interdisziplinären Sprechstunden erklären Fachpersonen den Befund und beantworten Fragen. Frau Z. geht es heute gut. Sie habe dank der Antworten des Pathologen ein besseres Verständnis von Brustkrebs und der Therapien, die sie durchgemacht hat.

El exitoso tratamiento prenatal para atacar el tumor que se alojaba en el cuello del bebé representa una primicia mundial para este tipo de afecciones. Conoce los detalles de esta y otras noticias positivas de la semana.

A atriz Sofia Alves é a convidada de Daniel Oliveira no Alta Definição. Aos 52 anos, revisita momentos marcantes da vida e da carreira, entre provações duras e uma fé que considera inabalável. Sofia recorda o susto de ter enfrentado um tumor, a urgência da cirurgia e o longo período de incerteza, bem como o impacto emocional que isso teve na família. Revela também o episódio traumático da zona que quase lhe tirou a visão e a complexa recuperação que obrigou a equipa da novela a recorrer a efeitos especiais para a manter em cena. “Tenho plena noção do que é a vida. Num momento estamos, no outro… deixamos de estar”, confessa. Na conversa, fala ainda da menopausa precoce, da perda de amigos próximos e da forma como o silêncio, a natureza e a oração lhe servem de refúgio. Partilha a relação profunda com o marido, Celso, a alegria que encontra no neto e a ligação especial a Margarida, a jovem atriz com trissomia 21 com quem contracena e a quem chama “filha do coração”. “Sou muito grata. A vida ensinou-me a não desistir”, afirma. Ouça o Alta Definição, em podcast, emitido na SIC em 21 de fevereiro 2026.* A sinopse deste episódio foi criada com o apoio de IA. Saiba mais sobre a aplicação de Inteligência Artificial nas Redações da Impresa See omnystudio.com/listener for privacy information.

Are we finished ruining soda for you? NOPE! Never.

This episode of Lung Cancer Considered focuses on a case of a patient with extensive stage SCLC. SCLC is a highly lethal subtype of lung cancer, accounting for about 13% of new lung cancer diagnoses with high variability based on geography and socioeconomic factors. The standard treatment for ES-SCLC had been platinum + etoposide for several decades, but over the past 7 years, we have had several new paradigm shifts that have led to real survival gains. To discuss current state of the art management, Guests: Raffaele Califano, Consultant at the Christie and Professor of Medical Oncology at Manchester University in the United Kingdom. Dr. Jessica Menis, thoracic medical oncologist at University Hospital of Verona, in Verona, Italy

Bone tumor treatment: when do you burn it and when do you freeze it? In this BackTable MSK Brief, Dr. Damian Dupuy joins Host Dr. Kavi Krishnasamy to discuss the technical nuances of radiofrequency ablation (RFA) and cryoablation, patient selection criteria, procedural strategies, and the importance of setting appropriate patient expectations. Dr. Dupuy also shares insights on preventing complications like cryomyositis and myoglobinuria, underscoring the balance between aggressive treatment and patient safety. Episode Outline 00:00 - Introduction 00:40 - Bone Tumor Interface and Time Under Treatment 05:10 - Patient Selection and Treatment Considerations 07:57 - Approach to Large Bony Lesions 12:37 - Best Treatment Modality: Cryoablation vs. RFA 13:38 - Managing Collateral Damage 15:58 - Navigating Patient Expectations Resources Dr. Damian E. Dupuy, MD, FACR https://www.linkedin.com/in/damian-e-dupuy-md-facr-6b080b1b/  Solitary painful osseous metastases: correlation of imaging features with pain palliation after radiofrequency ablation--a multicenter american college of radiology imaging network study https://pubmed.ncbi.nlm.nih.gov/23657892/

What could replace chemotherapy?In this episode of Beyond the Rounds, we explore cellular therapy, CAR-T cell therapy, tumor-infiltrating lymphocytes (TIL), and how modern immunotherapy is reshaping cancer treatment. Dr. Nolan Fisher sits down with hematologist and cellular therapy specialist Dr. Yazan Samhouri of Banner MD Anderson Cancer Center to break down how immune-based cancer treatments differ from traditional chemotherapy — and why the “last resort” label for CAR-T is quickly becoming outdated.This episode is designed for physicians, advanced practice providers, and clinicians who want a practical understanding of where cellular therapies fit in today's oncology landscape.What We Cover:• The difference between chemotherapy, immunotherapy, and cellular therapy• How CAR-T cell therapy works (Chimeric Antigen Receptor T-cells explained)• Tumor-infiltrating lymphocyte (TIL) therapy for solid tumors• Stem cell transplant vs. CAR-T — complementary or competing?• Cytokine release syndrome (CRS) and neurologic toxicity• Patient selection and referral timing• Why earlier referral matters in relapsed/refractory disease• Next-generation CAR-T and multi-antigen targeting• Off-the-shelf cellular therapies and the future of accessKey Topics for Clinicians:Hematologic malignanciesLymphoma and leukemiaMetastatic melanomaRelapsed/refractory cancerBridging therapy during CAR-T manufacturingFDA-approved immunotherapiesCancer clinical trialsMultidisciplinary cancer careAbout Our GuestDr. Yazan Samhouri is a specialist in hematology and cellular therapy at Banner MD Anderson Cancer Center. His clinical focus includes CAR-T therapy, stem cell transplantation, and advanced immunotherapeutic approaches for blood cancers and select solid tumors.DisclaimerThis podcast is intended for educational purposes only and is designed for a clinical audience. Any patient scenarios discussed are modified and de-identified to protect privacy. No protected health information (PHI) is disclosed. The information presented should not replace independent medical judgment or individualized patient care decisions.Subscribe to Beyond the Rounds for physician-focused conversations on clinical innovation, specialty collaboration, and evolving standards of care.

Port wine birthmark treatment -PTEN hamartoma tumor syndrome -Nanobubble technology for ichthyosis -Reactive granulomatosis dermatitis in kids -Cardiac issues in X-linked ichthyosis -Timolol for chronic wounds - Check out Luke's Urticaria CMEexperience! aaaaicsu.gathered.com/invite/KQe1wPZbJY Learnmore about the U of U Dermatology ECHOmodel! physicians.utah.edu/echo/dermatology-primarycare Want to donate to the cause? Do so here!Donate to the podcast: ⁠uofuhealth.org/dermasphere⁠Check out our video content on YouTube:www.youtube.com/@dermaspherepodcast⁠and VuMedi!: ⁠www.vumedi.com/channel/dermasphere/⁠The University of Utah's DermatologyECHO: ⁠⁠physicians.utah.edu/echo/dermatology-primarycare⁠ -Connect with us!- Web: ⁠⁠dermaspherepodcast.com/⁠⁠ - Twitter: @⁠DermaspherePC⁠- Instagram: dermaspherepodcast- Facebook: ⁠www.facebook.com/DermaspherePodcast/⁠- Check out Luke and Michelle's other podcast,SkinCast! ⁠⁠healthcare.utah.edu/dermatology/skincast/⁠⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our friends at:- ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge)- ⁠⁠www.levelex.com/games/top-derm⁠⁠ (A free dermatology game to learn more dermatology!

Cancer care is rapidly shifting toward precision medicine—treatment guided by a tumor's biology and biomarkers rather than where it starts in the body. HER2 is a protein on some cancer cells that can drive tumor growth. In this episode, we explore what it means for HER2 to be a target across multiple solid tumors, how […]

Cancer care is rapidly shifting toward precision medicine—treatment guided by a tumor's biology and biomarkers rather than where it starts in the body. HER2 is a protein on some cancer cells that can drive tumor growth. In this episode, we explore what it means for HER2 to be a target across multiple solid tumors, how […]

Wenn keine Chemotherapie mehr anschlägt, hilft manchmal eine individuelle Gentherapie. Wie funktioniert das - und für wen?Zwölf Mal hat der Krebspatient Torben Lorenz Chemotherapie bekommen, doch der Tumor wuchs weiter. Dann brachte eine CAR-T-Zell-Therapie die Wende – ein innovatives Verfahren, bei dem Immunzellen des Patienten gentechnisch zur spezialisierten Eingreiftruppe umprogrammiert werden.Die Personalisierte Medizin gilt als Gamechanger in der Onkologie und in weiteren Bereichen der Medizin. Unsere Autorin Daniela Remus hat Torben Lorenz in Heide besucht und Genforscher, Neurologen und Onkologen zu den Perspektiven von CAR-T-Zellen, Checkpoint-Inhibitoren und therapeutischer mRNA-Impfung befragt. Im Gespräch mit Host Korinna Hennig erklärt sie, wie man Krebszellen daran hindern kann, das Immunsystem auszutricksen. Sie berichtet über große Chancen, aber auch ökonomische Grenzen der Personalisierten Medizin. Es geht um verblüffende Durchbrüche, strukturelle Ungerechtigkeiten und offene Fragen - und am Ende um den Knackpunkt: Wie kann das für alle ermöglicht werden? HINTERGRUNDINFORMATIONENAktuelle Zahlen des RKI zur Überlebensrate bei Krebs: https://www.rki.de/DE/Aktuelles/Publikationen/Epidemiologisches-Bulletin/2026/05_26.pdf?__blob=publicationFile&v=4 CAR-T-Zell Therapie am UKE in HH https://www.uke.de/landingpage/zukunftsplan-2050/medizin-der-zukunft/02-lebende-medikamente-car-t-zell-immuntherapie.html Nobelpreis 2018 für Entdeckung der Checkpoint Inhibitoren https://www.aerzteblatt.de/archiv/nobelpreis-fuer-medizin-lahme-abwehr-scharf-machen-4650bfd8-f683-48df-aa52-3543bf18ae09 Übersicht über Immuntherapien vom Deutschen Krebsforschungszentrum (DKFZ) in Heidelberg: https://www.krebsinformationsdienst.de/immuntherapie Übersicht über Biontech-Studien zur mRNA-Impfung gegen Krebs: https://investors.biontech.de/de/news-releases/news-release-details/biontech-praesentiert-auf-der-44-jp-morgan-healthcare-konferenz UKE-Beteiligung an Zulassungsstudie zur Impfung gegen Hautkrebs: https://www.uke.de/landingpage/zukunftsplan-2050/medizin-der-zukunft/32-die-spritze-gegen-den-killer.html Ergebnisse der Phase 2-Studie zur Impfung gegen Hautkrebs: https://pubmed.ncbi.nlm.nih.gov/38246194/ Personalisierte Medizin - Der Fall Mila: https://www.doccheck.com/de/detail/articles/23611-mila-die-auserwaehlte Deutsches Krebsforschungszentrum (DKFZ) - Berechnung der Kosten einer typischen Medikamentenentwicklung: https://www.dkfz.de/aktuelles/pressemitteilungen/detail/was-kostet-die-entwicklung-eines-arzneimittels-wirklich Hörtipp: Podcast “Die Ernährungsdocs”: https://www.ardaudiothek.de/sendung/die-ernaehrungs-docs-essen-als-medizin/urn:ard:show:c9684369f9824d59/Habt ihr Feedback oder einen Lifehack aus der Welt der Wissenschaft? Schreibt uns an synapsen@ndr.de.Hier geht's zur Synapsenseite:https://www.ndr.de/nachrichten/podcastsynapsen100.htmlHier geht's zu ARD Gesund:https://www.ndr.de/ratgeber/gesundheit

Wenn keine Chemotherapie mehr anschlägt, hilft manchmal eine individuelle Gentherapie. Wie funktioniert das - und für wen?Zwölf Mal hat der Krebspatient Torben Lorenz Chemotherapie bekommen, doch der Tumor wuchs weiter. Dann brachte eine CAR-T-Zell-Therapie die Wende – ein innovatives Verfahren, bei dem Immunzellen des Patienten gentechnisch zur spezialisierten Eingreiftruppe umprogrammiert werden.Die Personalisierte Medizin gilt als Gamechanger in der Onkologie und in weiteren Bereichen der Medizin. Unsere Autorin Daniela Remus hat Torben Lorenz in Heide besucht und Genforscher, Neurologen und Onkologen zu den Perspektiven von CAR-T-Zellen, Checkpoint-Inhibitoren und therapeutischer mRNA-Impfung befragt. Im Gespräch mit Host Korinna Hennig erklärt sie, wie man Krebszellen daran hindern kann, das Immunsystem auszutricksen. Sie berichtet über große Chancen, aber auch ökonomische Grenzen der Personalisierten Medizin. Es geht um verblüffende Durchbrüche, strukturelle Ungerechtigkeiten und offene Fragen - und am Ende um den Knackpunkt: Wie kann das für alle ermöglicht werden? HINTERGRUNDINFORMATIONENAktuelle Zahlen des RKI zur Überlebensrate bei Krebs: https://www.rki.de/DE/Aktuelles/Publikationen/Epidemiologisches-Bulletin/2026/05_26.pdf?__blob=publicationFile&v=4 CAR-T-Zell Therapie am UKE in HH https://www.uke.de/landingpage/zukunftsplan-2050/medizin-der-zukunft/02-lebende-medikamente-car-t-zell-immuntherapie.html Nobelpreis 2018 für Entdeckung der Checkpoint Inhibitoren https://www.aerzteblatt.de/archiv/nobelpreis-fuer-medizin-lahme-abwehr-scharf-machen-4650bfd8-f683-48df-aa52-3543bf18ae09 Übersicht über Immuntherapien vom Deutschen Krebsforschungszentrum (DKFZ) in Heidelberg: https://www.krebsinformationsdienst.de/immuntherapie Übersicht über Biontech-Studien zur mRNA-Impfung gegen Krebs: https://investors.biontech.de/de/news-releases/news-release-details/biontech-praesentiert-auf-der-44-jp-morgan-healthcare-konferenz UKE-Beteiligung an Zulassungsstudie zur Impfung gegen Hautkrebs: https://www.uke.de/landingpage/zukunftsplan-2050/medizin-der-zukunft/32-die-spritze-gegen-den-killer.html Ergebnisse der Phase 2-Studie zur Impfung gegen Hautkrebs: https://pubmed.ncbi.nlm.nih.gov/38246194/ Personalisierte Medizin - Der Fall Mila: https://www.doccheck.com/de/detail/articles/23611-mila-die-auserwaehlte Deutsches Krebsforschungszentrum (DKFZ) - Berechnung der Kosten einer typischen Medikamentenentwicklung: https://www.dkfz.de/aktuelles/pressemitteilungen/detail/was-kostet-die-entwicklung-eines-arzneimittels-wirklich Hörtipp: Podcast “Die Ernährungsdocs”: https://www.ardaudiothek.de/sendung/die-ernaehrungs-docs-essen-als-medizin/urn:ard:show:c9684369f9824d59/Habt ihr Feedback oder einen Lifehack aus der Welt der Wissenschaft? Schreibt uns an synapsen@ndr.de.Hier geht's zur Synapsenseite:https://www.ndr.de/nachrichten/podcastsynapsen100.htmlHier geht's zu ARD Gesund:https://www.ndr.de/ratgeber/gesundheit

Send us a textGeorge Jerjian, had a life altering diagnosis in 2007 at the age of 52, a tumor that was meant to be life ending. All the odds were stacked against him, yet he survived to tell the tale! The experience changed the way he thought, and perceived life, and more specifically, as he approached retirement, he wanted to make sure his life continued with purpose. George is now a Retirement Mindset Mentor, and brings his real-world experience helping people aged 55–75 reframe aging and rediscover identity beyond job titles. Its a brilliant episode and highly relatable to literally anyone in any stage of life. Site: https://georgejerjian.com/Support the show

Osteosarcoma Webinar Series: David Ulmert, MD, PhD, an Associate Professor at UCLA, discusses his OutSmarting Osteosarcoma funded work (Because of Sydney) on high-throughput characterization of pathobiological responses in osteosarcoma tumors treated with LRRC15-targeted radiotherapy to uncover curative co-treatment approaches.Dr. Ulmert will discuss his lab's work investigating how osteosarcoma responds to LRRC15-targeted radiotherapy, with patient translation anticipated this year. Using high-throughput technologies, the team will identify biomarkers, predictive models, and key transcriptional regulators driving the TGFβ–LRRC15 axis. He will review how radiopathobiological changes and immune reprogramming are being mapped to uncover druggable events and inform co-treatment strategies, accelerating near-term impact on patient studies and next-generation therapeutic development.Dr. David Ulmert is an expert in oncology and biotechnology, specializing in cancer biomarkers and targeted therapies. His research focuses on antigens secreted by luminal tissues as novel cancer-specific targets and circulating biomarkers. He developed high-affinity antibodies against androgen receptor-regulated enzymes hK2 and PSA, now in clinical trials across the US, Europe, and Australia—in collaboration with Janssen—for radioimmunotheranostics, CAR-T therapy, and bispecific targeting. His lab also developed DUNP19, an LRRC15-targeting antibody licensed to Lantheus, with a Phase 1 trial in osteosarcoma planned for 2025. Dr. Ulmert leads UCLA's Preclinical Theranostics Program and conducts population-based studies on cancer biomarkers and risk factors with international collaborators. He is widely recognized for advancing prostate cancer research and translational immunotheranostics.

  ⏰

What if the most powerful cancer treatments already exist — but aren't being offered because they fall outside the guidelines?In this episode of Integrative Cancer Solutions, Dr. Michael Karlfeldt sits down with world-renowned interventional radiologist and oncology innovator Dr. Syed Hasnain Haider-Shah to explore why modern cancer care often prioritizes protocols over patients. From catheter-directed chemotherapy and tumor embolization to immune-based strategies, photobiomodulation, and precision nutrition, Dr. Shah reveals how advanced cancer treatments are being used globally — especially in China — while remaining largely inaccessible in the U.S.This conversation dives deep into the limitations of chemotherapy and radiation, the intelligence of cancer stem cells, immune system suppression, cancer cachexia, and why integrative, individualized approaches give patients their best chance at long-term survival. If you or someone you love is navigating a cancer diagnosis and searching for real options beyond “standard of care,” this episode is essential listening.Key Takeaways:5:20 Radiation therapy risks and how to support recovery nutritionally11:46 Why systemic chemotherapy often fails and selects for aggressive cancer cells12:17 Catheter-directed chemotherapy: targeting tumors without poisoning the body16:25 The immune system as the most powerful anti-cancer weapon26:37 Tumor embolization: starving cancer by cutting off its blood supply34:50 Why advanced cancer therapies thrive in China but are restricted in the U.S.Resources Mentioned:Williams Cancer Institute (Mexico) – https://williamscancerinstitute.comPhotobiomodulation / Intravenous Light Therapy (General Overview) – https://pubmed.ncbi.nlm.nih.gov Want to guest on our shows?Calendly Link for Integrative Lyme Solutions: https://calendly.com/drmichaelk/integrative-lyme-solutions-podcast-interviewCalendly Link for Integrative Cancer Solutions: https://calendly.com/drmichaelk/podcast-interviewCalendly Link for Dr. K Show: https://calendly.com/drmichaelk/dr-k-show-interview Breaking Free From Lyme: A Comprehensive Guide to Healing and Recovery-URL: https://store.thekarlfeldtcenter.com/products/breaking-free-from-lyme-Price: $24.99-Discount Code: LYMEPODCASTUnleashing 10X Power: A Revolutionary Approach to Conquering Cancer-URL: https://store.thekarlfeldtcenter.com/products/unleashing-10x-power-Price: $24.99-Discount Code: CANCERPODCAST1Healing Within: Unraveling the Emotional Roots of Cancer-URL: https://store.thekarlfeldtcenter.com/products/healing-within-Price: $24.99-Discount Code: CANCERPODCAST2The Science and Spirit of Transformation: A Holistic Guide to Elevating Health, Consciousness, and Purpose-URL: https://store.thekarlfeldtcenter.com/products/the-science-and-spirit-of-transformation-Price: $24.99-Discount Code: DRKSHOWPODCAST -----------------------------------------------A Better Way to Treat Cancer: A Comprehensive Guide to Understanding, Preventing and Most Effectively Treating Our Biggest Health ThreatGrab my book here: https://www.amazon.com/dp/B0CM1KKD9X?ref_=pe_3052080_397514860 Unleashing 10X Power: A Revolutionary Approach to Conquering CancerGet it here: https://store.thekarlfeldtcenter.com/products/unleashing-10x-powerPrice: $24.99100% Off Discount Code: CANCERPODCAST1 Healing Within: Unraveling the Emotional Roots of CancerGet it here: https://store.thekarlfeldtcenter.com/products/healing-withinPrice: $24.99100% Off Discount Code: CANCERPODCAST2-----------------------------------------------Integrative Cancer Solutions was created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com

Steve Brown, Founder and CEO and Lisa Booth, Vice President of Operations of CureWise, are both cancer survivors, which led them to develop an AI-powered tumor board platform to advance cancer diagnoses and treatment. This approach to precision medicine provides patients with the opportunity to better understand their specific condition, educating them about possible courses of action that may be more appropriate than the standard of care.  The platform also helps patients find relevant clinical trials and manage the side effects of their treatments. Steve explains, "So the mission really is to harness AI to advance cancer care. And ultimately, for that reason, anybody who's touched by cancer is hopeful that we will be making more progress toward cures for cancer. And we believe that that's going to happen through precision medicine, which really means recognition that everybody's cancer is unique. And at some point, we're going to treat cancer that way because we're going to know enough about how it all works. We're going to be able to individualize care. So our mission is to advance that cause."   Lisa elaborates, "When Steve and I started working together, one of the things I said was that I needed a way as a patient to be able to access different perspectives of a radiologist, an interventional radiologist, a pathologist, a geneticist, an oncologist, etc. And I can get that in Seattle, but most of the people I work with can't, meaning the patients and my friends in the cancer community don't have access to that because they don't exist in their communities."   #CancerCare #AI #PrecisionMedicine #PatientEmpowerment #HealthTech #CancerSurvivors #DigitalHealth #Oncology #TumorBoard #ClinicalTrials #HealthcareInnovation #PatientAdvocacy #PatientLedInnovation #CancerAndAI #TumorBoardTech #AIForPatients #SteveBrownAI #LisaBoothSurvivor #MedicalAutonomy #HealthTechWithHeart #NOfOneMedicine curewise.com Listen to the podcast here

Steve Brown, Founder and CEO and Lisa Booth, Vice President of Operations of CureWise, are both cancer survivors, which led them to develop an AI-powered tumor board platform to advance cancer diagnoses and treatment. This approach to precision medicine provides patients with the opportunity to better understand their specific condition, educating them about possible courses of action that may be more appropriate than the standard of care.  The platform also helps patients find relevant clinical trials and manage the side effects of their treatments. Steve explains, "So the mission really is to harness AI to advance cancer care. And ultimately, for that reason, anybody who's touched by cancer is hopeful that we will be making more progress toward cures for cancer. And we believe that that's going to happen through precision medicine, which really means recognition that everybody's cancer is unique. And at some point, we're going to treat cancer that way because we're going to know enough about how it all works. We're going to be able to individualize care. So our mission is to advance that cause."   Lisa elaborates, "When Steve and I started working together, one of the things I said was that I needed a way as a patient to be able to access different perspectives of a radiologist, an interventional radiologist, a pathologist, a geneticist, an oncologist, etc. And I can get that in Seattle, but most of the people I work with can't, meaning the patients and my friends in the cancer community don't have access to that because they don't exist in their communities."   #CancerCare #AI #PrecisionMedicine #PatientEmpowerment #HealthTech #CancerSurvivors #DigitalHealth #Oncology #TumorBoard #ClinicalTrials #HealthcareInnovation #PatientAdvocacy #PatientLedInnovation #CancerAndAI #TumorBoardTech #AIForPatients #SteveBrownAI #LisaBoothSurvivor #MedicalAutonomy #HealthTechWithHeart #NOfOneMedicine curewise.com Download the transcript here

Die Zahlen sind eindrücklich: Mehr als jede dritte Frau und jeder zweite Mann in der Schweiz sind im Lauf ihres Lebens von einer Krebserkrankung betroffen. Klingt nach viel. Gleichzeitig heisst es: Weltweit könnten vier von zehn Krebs-Erkrankungen verhindert werden. Wir ordnen das ein. Wie steht es um Prävention, Behandlung und Krebsforschung? So viel vorweg: In einigen Bereichen ist die Schweiz Spitze, in anderen hat sie enorm aufzuholen. Der Spezialist erklärt das und sagt auch, weshalb es wichtig ist zu verstehen, dass unser Körper funktioniert wie ein Kopiergerät. ____________________ Habt Ihr Fragen oder Themen-Inputs? Schreibt uns gerne per Mail an newsplus@srf.ch oder sendet uns eine Sprachnachricht an 076 320 10 37. ____________________ In dieser Episode zu hören: - Anna Baptista, Pflegeassistentin und Begleiterin von Betroffenen bei der Krebsliga - Roger von Moos, Direktor des Tumor- und Forschungszentrums im Kantonsspital Graubünden ____________________ Link: - SRF-Sendung "Puls": https://www.srf.ch/play/tv/puls/video/diagnose-krebs---was-nun?urn=urn:srf:video:69107237-c2cd-4495-b32d-0def4e53f399 ____________________ Team: - Moderation: Susanne Stöckl - Produktion: Marisa Eggli - Mitarbeit: Gabriel Gasser ____________________ Das ist «News Plus»: In einer Viertelstunde die Welt besser verstehen – ein Thema, neue Perspektiven und Antworten auf eure Fragen. Unsere Korrespondenten und Expertinnen aus der Schweiz und der Welt erklären, analysieren und erzählen, was sie bewegt. «News Plus» von SRF erscheint immer von Montag bis Freitag um 16 Uhr rechtzeitig zum Feierabend.

You're about to biopsy a renal lesion; should you ablate at the same time? In this episode of the BackTable Podcast, host Michael Barraza talks with Dr. Steven Huang from MD Anderson Cancer Center about building an efficient and effective renal biopsy and ablation service line. --- This podcast is supported by: Varian IntelliBlatehttps://www.varian.com/products/interventional-solutions/microwave-ablation-solutions --- SYNPOSIS Dr. Huang first covers referral patterns and the typical pathway that patients take to end up in his clinic. The discussion covers the types of lesions he treats, imaging requirements, and criteria for patient eligibility. He emphasizes the importance of shared decision making when deciding between active surveillance, interventional treatment, and partial nephrectomy. Dr. Huang explains his preferred procedural approach and ablation modalities, including cryo, microwave (MWA), and radiofrequency ablation (RFA). He shares his experiences with challenging cases and integrating new technologies like histotripsy and the Siemens interventional package. They also discuss the possibility of a preoperative embolization for larger lesions that could be susceptible to the heat sink effect. Both experts emphasize the importance of collaboration with urologists and ensuring patient safety and expectations. They also touch on the future of the field, discussing the use of AI and robotics. --- TIMESTAMPS 00:00 - Introduction 02:17 - Training Programs at MD Anderson03:23 - Referral Patterns for Renal Ablations07:25 - Patient Management and Virtual Consultations10:59 - Ablation Techniques and Device Selection26:44 - Challenges and Complications27:25 - Approach to Lesions Near Renal Vasculature28:02 - Patient Expectations and Urologist Collaboration33:26 - Post-Procedure Care and Patient Recovery35:30 - Managing Recurrences and Multiple RCCs47:17 - Closing Remarks

Einer der größten Killer der Menschheitsgeschichte könnte besiegt werden. Neue Krebsimpfstoffe könnten innerhalb eines Jahrzehnts Realität werden. In der Forschung vorn dabei ist das Mainzer Unternehmen Biontech. Den „Tagesanbruch" gibt es auch zum Nachlesen unter [t-online.de/tagesanbruch](https://www.t-online.de/tagesanbruch) Anmerkungen, Lob und Kritik gern an podcasts@t-online.de Den „Tagesanbruch“-Podcast gibt es immer montags bis freitags ab 6 Uhr zum Start in den Tag vorgelesen von einer freundlichen KI-Stimme – am Wochenende mit einer tiefgründigeren Diskussion. Verpassen Sie keine Folge und abonnieren Sie uns bei [Spotify] https://open.spotify.com/show/3v1HFmv3V3Zvp1R4BT3jlO?si=klrETGehSj2OZQ_dmB5Q9g), [Apple Podcasts](https://itunes.apple.com/de/podcast/t-online-tagesanbruch/id1374882499?mt=2), [Amazon Music](https://music.amazon.de/podcasts/961bad79-b3ba-4a93-9071-42e0d3cdd87f/tagesanbruch-von-t-online) oder überall sonst, wo es Podcasts gibt. Wenn Ihnen der Podcast gefällt, lassen Sie gern eine Bewertung da.

As part of IASLC's ongoing series of Lung Cancer Considered podcast episodes in world languages, Dr. Ece Cali moderates a discussion in Turkish with Dr. Irfan Çiçin and Dr. Fulden Yumuk. The episode is part of our Virtual Tumor Board series and focuses on immunotherapy for non-small cell lung cancer (NSCLC).

In this JCO Precision Oncology Article Insights episode, host Dr. Jiasen He summaries the article, "Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors," by Hassoun et al. TRANSCRIPT Jiasen He: Hello, and welcome to the JCO Precision Oncology Article Insights. I'm your host, Jiasen He, and today, we'll be discussing the JCO Precision Oncology article, "Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors," by Dr. Rebecca Hassoun and colleagues. Traditionally, treatment response for solid tumors has relied on imaging, which focuses on visible anatomic changes in the tumor. However, imaging does not always reflect molecular or cellular changes and cannot detect microscopic disease, which is clinically important and often linked to relapse. Liquid biopsy, on the other hand, is minimally invasive and can be used for cancer monitoring by analyzing circulating biomarkers in biofluids such as blood. One type of liquid biopsy is circulating tumor DNA, or ctDNA, which measures small fragments of DNA released by tumor cells into the bloodstream. ctDNA can allow precise monitoring of tumor-specific mutations and be a powerful tool for assessing treatment responses. ctDNA has already been applied in clinical settings for cancers such as non-small cell lung cancer and breast cancer, etcetera. However, there is still limited data on the use of ctDNA for germ cell tumors. Germ cell tumors are the most common malignancy affecting men aged 15 to 35 years. Accurate risk stratification and disease monitoring is key to risk-adapted therapy, maximizing the chance of cure while minimizing side effects. One unique tool we use currently for diagnosis, staging, and monitoring is serum tumor markers, such as AFP, beta-hCG, and LDH. However, these markers have limitations, including false elevation in certain clinical scenarios, and studies have shown that they can be normal in up to 40 percent of patients with germ cell tumor. This creates an unmet need for other sensitive and specific biomarkers to improve patient care. In this paper, the authors investigated the use of ctDNA in a cohort of patients with germ cell tumor at various disease time points. They compared ctDNA results with traditional serum tumor markers to evaluate whether ctDNA can predict relapse and survival outcomes. This multi-institutional retrospective study included patients with stage I, II, and III germ cell tumors, primarily testicular cancer, who had at least one ctDNA test result. ctDNA was evaluated longitudinally at different time points, including pre-orchiectomy, during the molecular residual disease, or MRD, window, defined as 1 to 12 weeks post-orchiectomy but before primary therapy, and during the surveillance window, defined as more than 12 weeks post-orchiectomy or follow retroperitoneal lymph node dissection or post-chemotherapy. ctDNA analysis was performed using a tumor-informed 16 multiplex PCR next-generation sequencing assay. A total of 324 plasma samples were analyzed from 74 patients in this cohort. The majority had stage I disease, around 40 percent, and nonseminomatous histology, around 70 percent. 15 patients were evaluated in the pre-orchiectomy window, and only one patient tested negative for ctDNA. This patient had stage I disease. The authors further assessed ctDNA positivity in both the MRD window and surveillance window, evaluating its association with event-free survival. They found that ctDNA outperformed serum tumor markers in both settings. ctDNA positivity was associated with significantly worse event-free survival compared with ctDNA-negative patients. Among the 14 patients with stage II to III disease who had ctDNA assessed in both the MRD window and surveillance window, nine patients consistently had a negative ctDNA or converted from positive to negative over time. In contrast, five patients demonstrated persistent ctDNA positivity, and all of these patients subsequently relapsed. Among the 38 patients who had both ctDNA and serum tumor marker tests during the MRD window, nine patients showed discordant biomarker results. Of these, 6 patients were ctDNA-negative but serum tumor marker-positive, and one of them experienced recurrence. Three patients were ctDNA-positive but serum tumor marker-negative, and one of these patients also recurred. During the surveillance window, 46 patients had both biomarkers available, and 10 showed discordant results. Three patients were ctDNA-negative but serum tumor marker-positive, and none of them recurred. In contrast, all seven patients who were ctDNA-positive but serum tumor marker-negative experienced recurrence. This intriguing data strongly support the potential role of ctDNA in patients with stage I, II, and III germ cell tumors. However, as the authors noted, the retrospective nature of the study presents limitations, as treatment approaches, imaging schedules, and the timing of testing were not standardized, and ctDNA testing varies among participating institutions. Larger prospective trials with standardized protocols and long-term follow-up will be essential to validate these findings and determine how ctDNA can be reliably integrated into clinical practice. Thank you for tuning in to JCO Precision Oncology Article Insights. Don't forget to subscribe and join us next time as we explore more groundbreaking research shaping the future of oncology. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Nova temporada do Pipoca TdC no ar!

In today's Beating Cancer Daily episode, Saranne explores creating a living legacy with excitement and optimism. As someone who has beaten Stage IV cancer for 30 years, Saranne shares her perspective on why it's essential to consciously think about and enjoy crafting a legacy, regardless of the timeline we have. Join her as she discusses fun and creative ways to leave a lasting imprint, from recording books for loved ones to planting living markers of our time. Get ready to be inspired and discover how embracing the concept of legacy can bring joy and depth to our lives as we beat cancer daily together.2025 People's Choice Podcast Awards Best Health Series FinalistRanked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025,and #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 to 2025. Beating Cancer Daily is listened to in 140 countries across 7 continents and features over 400 original daily episodes hosted by Stage IV survivor Saranne Rothberg. To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_Suggestions To sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/ Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne  

Send a textYour heart sinks when a dog's CT shows a primary liver tumor plus extra lesions. Ours used to as well—until we dug into data showing how often those additional masses are actually benign. In this conversation with surgical oncologists Drs. Samuel Burkhardt and Hunter Piegols, we rethink what “multiple hepatic lesions” really means, and how that shift can change everything from pre-op counseling to what you sample in the OR.We walk through their study design—primary liver tumors paired with additional lesions verified by surgical exploration and histopathology—and why imaging alone couldn't separate benign from malignant with confidence. You'll hear practical guidance on interpreting CT findings without leaping to metastasis, framing owner conversations to avoid a falsely negative outlook, and planning targeted biopsies that refine staging and inform follow-up. We also tackle the language problem: nodule versus mass. Without common definitions, clinicians and researchers risk misreading severity and muddying the literature. The case for cross-disciplinary standards and working groups is compelling.Looking ahead, we explore tools that could improve preoperative decisions: contrast-enhanced ultrasound, more rigorous imaging criteria adapted from human medicine, and the promise of liquid biopsy and biomarkers to flag “bad actor” hepatocellular carcinomas. We discuss sample-size limits in veterinary studies, the value of multi-institutional collaboration, and related puzzles like what a solitary pulmonary nodule really means for prognosis. Along the way, you'll pick up succinct surgical maxims, practical tips for histopath submission, and a reminder that small resets outside the clinic help us think clearly when cases get complex.If this conversation helps you reframe your next liver case, share it with a colleague, subscribe for more evidence-based episodes, and leave a review so others can find the show.JAVMA article: https://doi.org/10.2460/javma.25.07.0514INTERESTED IN SUBMITTING YOUR MANUSCRIPT TO JAVMA ® OR AJVR ® ? JAVMA ® : https://avma.org/JAVMAAuthors AJVR ® : https://avma.org/AJVRAuthorsFOLLOW US:JAVMA ® : Facebook: Journal of the American Veterinary Medical Association - JAVMA | Facebook Instagram: JAVMA (@avma_javma) • Instagram photos and videos Twitter: JAVMA (@AVMAJAVMA) / Twitter AJVR ® : Facebook: American Journal of Veterinary Research - AJVR | Facebook Instagram: AJVR (@ajvroa) • Instagram photos and videos Twitter: AJVR (@AJVROA) / Twitter JAVMA ® and AJVR ® LinkedIn: https://linkedin.com/company/avma-journals

Send us a textWe're going back Down Under for a really impressive comeback story. Olli Bryers was what we Americans would stereotype as a young, carefree, adventurous Australian who liked to surf, backpack, travel, and occasionally party. Usually, that youthful bliss only gets interrupted when the real world says that maybe you need to find a job to finance this lifestyle, or get serious about a long-term career path. But in Olli's case, that jolt came in his early 20s from the discovery of a spinal tumor that necessitated a surgery that could rob his ability to ever walk again. Fortunately, the doctors were successful in removing the tumor and it was benign. Improbably, just six months later, Olli toed the starting line of his very first triathlon, in his hometown of Newcastle in the state of New South Wales. But that wasn't the end of this amazing comeback story because Olli never would have completed the race without the generosity of another competitor. His finish time was 1:27:16, placing him 114th out of 304 who completed it. But I have a feeling that this is only the beginning for this young Aussie, who as you'll hear in this interesting chat has a lot of gratitude and a very mature attitude about the meaning of his surviving this ordeal intact, including how to approach life and being kinder to those around you. Plus, I've got to say that Olli told me I'm “cruisy,” which I took as a compliment. You'll have to look that one up in your Aussie slang dictionary.Olli BryersInstagram @olli.bryersBill Stahlsilly_billy@msn.comFacebook Bill StahlInstagram and Threads @stahlor and @we_are_superman_podcastYouTube We Are Superman PodcastSubscribe to the We Are Superman Newsletter!https://mailchi.mp/dab62cfc01f8/newsletter-signupSubscribe to our Substack for my archive of articles of coaching tips developed from my more than three decades of experience, wild and funny stories from my long coaching career, the wit and wisdom of David, and highlights of some of the best WASP episodes from the past that I feel are worthwhile giving another listen.Search either We Are Superman Podcast or @billstahl8Register for the American Heroes Run: https://ultrasignup.com/register.aspx?did=133138

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Benign Bone Tumors⁠⁠ from the Oncology section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

What a day. Believe it or not, these are feel good stories. Join me. — Support and sponsor this show! Venmo Tip Jar: @wellthatsinteresting Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@wellthatsinterestingpod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Bluesky: @wtipod Threads: @wellthatsinterestingpod Twitter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@wti_pod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Listen on YouTube!! Oh, BTW. You're interesting. Email YOUR facts, stories, experiences... Nothing is too big or too small. I'll read it on the show: wellthatsinterestingpod@gmail.com WTI is a part of the Airwave Media podcast network! Visit AirwaveMedia.com to listen and subscribe to other incredible shows. Want to advertise your glorious product on WTI? Email me: wellthatsinterestingpod@gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices

February 2026 Journal Club Podcast Title: Maximizing Tumor Resection and Managing Cognitive Attentional Outcomes: Measures of Impact of Awake Surgery in Glioma Treatment To read journal article: https://journals.lww.com/neurosurgery/fulltext/2026/02000/maximizing_tumor_resection_and_managing_cognitive.15.aspx Authors: Silvio Sarubbo and Luca Zigiotto Guest Faculty: Pablo Valdes Resident Planner: Alexander Himstead Podcast Committee Vice Chair/Moderator: Martin Pham

Getting a cancer diagnosis today can mean something very different than it meant a few decades ago.  Cancer is still deadly. But thanks to advances in detection and treatment, cancer for some people has turned into a manageable condition. A report from the American Cancer Society out this week shows that for the first time that the five-year survival rate for all cancers has reached 70 percent. Tumors are being found at earlier stages, when treatment can be more effective. Surgery and radiation have gotten more precise.  Researchers have refined their understanding of different types of cancers and developed new drugs that zero in on the unique biology of specific tumors.Maybe most importantly, researchers are figuring out how to use the body's own immune system to fight cancer in ways that doctors couldn't have imagined 20 years ago.  MPR News host Angela Davis talks with her guests about how cancer treatments are improving.Guests: Dr. Emil Lou is a medical oncologist and professor at the University of Minnesota Medical School who sees patients at M Health Fairview Masonic Cancer Clinic. He specializes in gastrointestinal cancers, such as colorectal and pancreas cancers, and is also involved in cancer research.  Dr. Rachel L McCaffrey is a breast surgical oncologist at Allina Health who specializes in treating breast cancer. 

Featuring an interview with Dr Scott Kopetz, including the following topics:  Circulating tumor DNA (ctDNA)-guided adjuvant chemotherapy de-escalation in the treatment of Stage III colon cancer from the ctDNA-negative cohort of the DYNAMIC-III trial (0:00) Prognostic and predictive role of ctDNA in the management of Stage III colon cancer treated with celecoxib: Findings from the CALGB (Alliance)/SWOG 80702 trial (8:01) Phase III ALTAIR study comparing trifluridine/tipiracil to placebo for patients with molecular residual disease after curative resection of colorectal cancer (CRC); a methylation-based, tissue-free ctDNA test (12:51) ctDNA with locally advanced mismatch repair-deficient/microsatellite instability-high solid tumors; real-world evidence regarding ctDNA with resected CRC (17:31) CME information and select publications

Featuring an interview with Dr Scott Kopetz, including the following topics: Circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) and survival among patients with resectable colorectal cancer (CRC) in the CIRCULATE-Japan GALAXY trial (0:00) ctDNA for detection of MRD in patients with CRC in the BESPOKE CRC and INTERCEPT trials (3:11) Clinical utility of including ctDNA monitoring in standard CRC surveillance (11:11) ctDNA analysis guiding adjuvant therapy for CRC in the DYNAMIC and CIRCULATE-North America trials (15:52) CME information and select publications

In cancer research, the “seed and soil” hypothesis posits that the tumor is like a seed of misbehaving cells taking root in the body. Whether it grows—and where it grows—depends on the conditions, or soil. Since this hypothesis was proposed more than 100 years ago, most research and treatments have focused on the seed, or tumor. For nearly 50 years, Rakesh Jain has been studying the soil. But in a seed-focused field, his work was seen as wasteful and radical. Now, that very same research has led to seven FDA-approved treatments for diseases including lung and liver cancer, and earned him a National Medal of Science in 2016. Host Flora Lichtman talks with Jain about how his fringe idea led to lifesaving cancer treatments. Guest: Dr. Rakesh K. Jain studies the biology of tumors at Harvard Medical School and Massachusetts General Hospital as a professor of radiation oncology.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.